Quick Answer
Lyra Therapeutics, Inc. reported Total Assets of $36.11 million for the year ending 2025.
- Lyra Therapeutics, Inc. showed a decrease of -45.6% in Total Assets from 2024 to 2025.
- This data is from Lyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $40.77 million | Q2 2020: $92.72 million | Q3 2020: $87.33 million | Q1 2021: $72.92 million | Q2 2021: $76.33 million | Q3 2021: $67.76 million | Q1 2022: $47.35 million | Q2 2022: $130.04 million | Q3 2022: $119.46 million | Q1 2023: $93.87 million | Q2 2023: $125.68 million | Q3 2023: $120.58 million | Q1 2024: $141.53 million | Q2 2024: $94.58 million | Q3 2024: $78.76 million | Q1 2025: $56.32 million | Q2 2025: $52.57 million | Q3 2025: $43.71 million.
- Over the full 7 years of available data (2019 to 2025), Lyra Therapeutics, Inc.'s Total Assets has grown by 141.3%.
- Historical annual values: Fiscal year 2025: $36.11 million | Fiscal year 2024: $66.35 million | Fiscal year 2023: $142.60 million | Fiscal year 2022: $109.97 million | Fiscal year 2021: $54.87 million | Fiscal year 2020: $80.83 million | Fiscal year 2019: $14.96 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: